REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “ ...

Core Viewpoint - Pulmonx reported better-than-expected quarterly earnings, with a revenue of $21.50 million, surpassing analyst estimates of $20.78 million, and an EPS of ($0.34), exceeding the consensus estimate of ($0.40) by $0.06 [1] Financial Performance - The company had a negative return on equity of 77.58% and a negative net margin of 61.91% [1] - The stock opened at $1.45, with a market cap of $59.81 million, a PE ratio of -1.03, and a beta of 0.07 [2] - The fifty-day simple moving average is $2.04, and the 200-day simple moving average is $1.83 [2] - The stock has a fifty-two week low of $1.31 and a high of $9.37 [2] Analyst Ratings - Weiss Ratings restated a "sell (e+)" rating, while Lake Street Capital decreased their price target from $8.00 to $4.00 with a "buy" rating [4] - D. Boral Capital reaffirmed a "buy" rating with a price objective of $14.00, and Wall Street Zen upgraded the stock from "sell" to "hold" [4] - Currently, five analysts have rated the stock as "buy," four as "hold," and one as "sell," with an average price target of $6.81 [4] Institutional Activity - XTX Topco Ltd acquired a new stake worth about $149,000, and Norges Bank acquired a position valued at approximately $392,000 [5] - Jane Street Group LLC increased its stake by 3,328.7%, now owning 88,631 shares valued at $230,000 [5] - Bank of America Corp DE boosted its position by 556.6%, owning 481,268 shares worth $1,246,000 [5] - Institutional investors and hedge funds own 91.04% of the company's stock [5] Company Overview - Pulmonx Corporation focuses on bronchoscopic lung volume reduction for patients with severe emphysema, with its flagship product being the Zephyr® Endobronchial Valve System [6] - The Zephyr Valve received CE mark approval in Europe in 2008 and FDA approval in the U.S. in 2018, gaining adoption in leading respiratory and thoracic centers [8]

Core Insights - The FDA has granted full approval to IMDELLTRA (tarlatamab-dlle) for treating adult patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy, marking it as a recognized standard of care [1][2][8] - The Phase 3 DeLLphi-304 trial demonstrated that IMDELLTRA reduced the risk of death by 40% and extended median overall survival by more than five months compared to standard chemotherapy [1][3][4] Company Developments - Amgen is committed to advancing IMDELLTRA for earlier stages of small cell lung cancer and earlier lines of therapy, emphasizing its dedication to providing transformative medicines for challenging cancers [2][3] - The safety profile of IMDELLTRA in the DeLLphi-304 trial showed fewer Grade 3 or greater adverse events compared to chemotherapy (54% vs 80%), indicating a favorable safety profile [2][3] Clinical Trial Insights - The DeLLphi-304 study involved 509 patients and was the first global Phase 3 trial to show a significant survival benefit over chemotherapy for ES-SCLC [3][4] - Key secondary outcomes of the trial included progression-free survival and patient-reported outcomes, which further support the efficacy of IMDELLTRA [4] Treatment Landscape - IMDELLTRA targets DLL3, a protein expressed on 85-96% of SCLC cells, making it a promising option for patients with limited treatment alternatives [7][8] - The National Comprehensive Cancer Network (NCCN) has updated its guidelines to include tarlatamab as the only Category 1 preferred treatment option for this patient population [1][2] Future Directions - Amgen's development program for IMDELLTRA includes multiple ongoing clinical trials to evaluate its efficacy in various treatment settings, including combination therapies and earlier lines of treatment [5][6]

Group 1 - The article does not provide any specific content related to a company or industry [1]

分组1 - Pulmonx Corporation reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of +15.00% [1] - The company achieved revenues of $21.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.10% and showing an increase from $20.39 million year-over-year [2] - Over the last four quarters, Pulmonx has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed significantly, losing about 69.2% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $23.83 million, and for the current fiscal year, it is -$1.51 on revenues of $90.89 million [7] - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Financial Data and Key Metrics Changes - Total worldwide revenue for Q3 2025 was $21.5 million, a 5% increase from $20.4 million in Q3 2024, and a 4% increase on a constant currency basis [12] - US revenue in Q3 2025 was $14 million, a 1% increase from $13.8 million in the prior year [12] - International revenue for Q3 2025 was $7.5 million, a 15% increase compared to $6.6 million in the same period last year [12] - Gross margin for Q3 2025 was approximately 75%, up from 74% in the same period last year [12] - Net loss for Q3 2025 was $14 million, or $0.34 per share, compared to a $14.1 million net loss, or $0.36 per share, for the same period last year [15] - Adjusted EBITDA loss for Q3 2025 was $8.2 million, compared to $8.1 million in Q3 2024 [15] - Full year 2025 revenue guidance is updated to a range of $89-$90 million [16] Business Line Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $4.8 million, an increase of 29% compared to $3.7 million in the prior year [13] - Sales, general, and administrative expenses for Q3 2025 were $25.6 million, up 1% from $25.4 million in Q3 2024 [14] Market Data and Key Metrics Changes - The company added nine new US centers during Q3 2025 [12] - Growth in international revenue was driven by major markets in Europe, partially offset by a reduction of revenue from China [12] Company Strategy and Development Direction - The company aims to improve execution and accelerate profitable growth while focusing on areas with the highest return on capital [9][10] - The management acknowledges the need to realign spending with growth expectations to return to a sustainable path to profitability [9] - The company plans to prioritize projects that deliver the greatest impact and align with sustainable, profitable growth [17] Management's Comments on Operating Environment and Future Outlook - Management recognizes challenges in the US market, including slowed growth and the need for improved execution [8][9] - There is optimism about the potential to enhance growth by aligning underperforming territories with those performing well [9] - The management is committed to extending the cash runway and improving operating leverage [15][44] Other Important Information - The company has a market-leading product, the Zephyr valves, which fulfill a significant unmet need in severe emphysema patients [6] - The company has established sufficient reimbursement for its products in nearly all countries where it operates [7] Q&A Session Summary Question: Exploration of alternate strategic pathways - Management is focused on ensuring profitable business operations and is not ready to speculate on alternative strategies at this early stage [20][22] Question: Reasons for US growth deceleration despite new center additions - Management acknowledges the complexity of the situation and is optimistic about improving performance in underperforming territories [23] Question: Addressing patient referral and workup process complexities - Management agrees on the complexity and emphasizes the need for efficient processes to move patients through treatment [26][27] Question: Guidance revision and confidence in achieving targets - Management provides a realistic view on guidance, acknowledging that some growth initiatives have not met expectations but sees opportunities for improvement [36][38] Question: Extending cash runway and reallocating expenses - Management confirms that extending the cash runway involves reallocating expenses to areas with better returns rather than seeking external financing [42][44] Question: Specific areas to pull back on in strategy - Management is not ready to discuss specific areas for pullback but is analyzing data to make informed decisions moving forward [46][47]

Revenue and Financial Performance - Revenue for the three months ended September 30, 2025, was $21.5 million, a 5.4% increase from $20.4 million for the same period in 2024, with a gross margin of 74.7%[117] - For the nine months ended September 30, 2025, revenue was $67.9 million, up 13.2% from $60.0 million in the same period in 2024, with a gross margin of 73.0%[117] - Revenue increased by $1.1 million, or 5.5%, to $21.5 million for the three months ended September 30, 2025, compared to $20.4 million for the same period in 2024[145] - For the nine months ended September 30, 2025, revenue increased by $7.9 million, or 13.1%, to $67.9 million compared to $60.0 million in the same period in 2024[153] - Revenue from sales outside of the United States represented 36.8% of total revenue for the nine months ended September 30, 2025, compared to 32.4% for the same period in 2024[188] Net Loss and Financial Position - The company reported a net loss of $14.0 million for Q3 2025, compared to a net loss of $14.1 million in Q3 2024, and a net loss of $43.6 million for the nine months ended September 30, 2025, compared to $43.2 million for the same period in 2024[117] - As of September 30, 2025, the company had an accumulated deficit of $511.1 million and cash and cash equivalents of $76.5 million[117] - As of September 30, 2025, the company had cash and cash equivalents of $76.5 million, expected to fund operating expenses for at least 12 months[178] - Net cash used in operating activities was $25.3 million for the nine months ended September 30, 2025, primarily due to a net loss of $43.6 million[171] - The company expects to continue incurring net losses for the next several years and will require substantial additional funding[118] Expenses and Cost Management - Research and development expenses rose by $1.1 million, or 29.4%, to $4.8 million for the three months ended September 30, 2025, primarily due to increased clinical trial costs[148] - Selling, general and administrative expenses increased by $0.2 million, or 0.7%, to $25.6 million for the three months ended September 30, 2025, driven by higher advertising and marketing expenses[149] - Research and development expenses for the nine months ended September 30, 2025, increased by $1.3 million, or 9.9%, to $14.9 million, largely due to clinical trial costs[155] - Interest expense decreased by $0.3 million to $2.4 million for the nine months ended September 30, 2025, due to lower interest rates[157] - Interest expense on the CIBC Loan was $0.8 million for the three months ended September 30, 2025[168] Market and Operational Strategy - Approximately 93% of revenue for the nine months ended September 30, 2025, was generated in markets where the company sells directly[113] - The company is focused on expanding its commercial operations in the U.S. and internationally, with significant investments in sales and marketing[118] - The company has a dedicated patient reimbursement support team to assist in securing prior authorization approvals for treatments[125] - The company may undertake additional expenses to expand its commercial organization and enhance research and development efforts[177] Research and Development - The company is investing in research and development to enhance existing products and develop next-generation technologies, including the AeriSeal System, which is in a pivotal trial[129] Currency and Inflation Impact - A 10% change in foreign currency exchange rates would have impacted revenues by approximately $2.5 million and operating expenses by $1.6 million for the nine months ended September 30, 2025, resulting in a net impact of $0.9 million on net loss[188] - High inflation rates have led to increased costs in transportation, wages, and other operational expenses[189] - Inflation may affect the company's cost of labor, commercial support, manufacturing, and clinical trial expenditures[189] - The company does not believe inflation has materially impacted its financial position or results of operations to date[189] - If costs become subject to significant inflationary pressures, the company may struggle to offset these with increased revenues[189] - The inability to offset higher costs with increased revenues could harm the company's business and financial condition[189]

Core Insights - Pulmonx Corporation reported a total worldwide revenue of $21.5 million for Q3 2025, reflecting a 5% increase from $20.4 million in Q3 2024, and a 4% increase on a constant currency basis [4][9] - The company aims to leverage its operational foundation to expand Zephyr Valve treatment volumes while maintaining a commitment to sustainable, profitable growth [3][4] Financial Performance - U.S. revenue for Q3 2025 was $14.0 million, a 1% increase year-over-year, while international revenue reached $7.5 million, marking a 15% increase compared to Q3 2024 [4][9] - Gross profit for Q3 2025 was $16.1 million, with a gross margin of 75%, up from 74% in the same period last year [5][9] - Operating expenses increased by 4% to $30.4 million, driven by higher clinical, development, and commercial investments [5][9] - The net loss for Q3 2025 was $14.0 million, or $0.34 per share, slightly improved from a net loss of $14.1 million, or $0.36 per share, in Q3 2024 [6][9] 2025 Financial Outlook - Pulmonx updated its 2025 financial outlook, expecting total revenue to be in the range of $89 million to $90 million, with a gross margin of approximately 73% [7][9] - Total operating expenses for the full year 2025 are projected to be between $125 million and $126 million, including about $21 million in non-cash stock-based compensation [7][9] Leadership Changes - Glen French was reappointed as President and CEO, and Derrick Sung was appointed as COO and CFO [9]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest in AI technologies now [1][13] - The energy demands of AI technologies are highlighted as a critical concern, with data centers consuming as much energy as small cities, leading to potential crises in power supply [2][3] Investment Opportunity - A specific company is positioned as a key player in the AI energy sector, owning critical energy infrastructure assets that will benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is essential for supplying the energy needed for AI advancements [3][6] Market Position - The company is described as a "toll booth" operator in the AI energy boom, profiting from the surge in energy demand driven by AI technologies [4][5] - It is involved in U.S. LNG exportation, which is expected to grow under the current administration's energy policies [7] Financial Health - The company is noted for being debt-free and having a significant cash reserve, equating to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened with debt [8][10] - The stock is trading at less than 7 times earnings, indicating it is undervalued relative to its potential [10][12] Strategic Advantages - The company has a unique footprint in nuclear energy, which is seen as a future source of clean and reliable power [14] - It is capable of executing large-scale engineering, procurement, and construction projects across various energy sectors, enhancing its competitive edge [7][8] Market Trends - The article discusses the broader trends of AI infrastructure supercycles, onshoring driven by tariffs, and the surge in U.S. LNG exports as significant factors influencing the market [14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, making investments in AI increasingly attractive [12]

Group 1: Penny Stocks Overview - Five penny stocks to watch include Beyond Meat, Strive, VSee Health, Pulmonx, and Datavault AI, identified by MarketBeat's stock screener tool [2] - Penny stocks are defined as shares of very small or microcap companies trading at low per-share prices, traditionally under $1 but commonly under $5 in the U.S. [2] - These stocks often trade on over-the-counter markets, characterized by low liquidity, wide bid-ask spreads, high volatility, and a greater risk of price manipulation and loss [2] Group 2: Company Profiles - Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products across various platforms including beef, pork, and poultry, with distribution through grocery and foodservice channels [3] - Strive (Asset Entities Inc.) provides social media marketing and content delivery services, focusing on platforms like Discord and TikTok, and offers investment education and marketing services [4] - Pulmonx Corporation specializes in minimally invasive devices for chronic obstructive pulmonary diseases, offering products like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System [5] - Datavault AI Inc. operates data management and supercomputer platforms, providing data technology and software solutions, previously known as WiSA Technologies, Inc. [6]